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Introduction
Rabies, a severe encephalitis of mammals, is caused by the members of the lyssavirus genus of the Rhabdoviridae family, order Mononegavirales [1] . The disease is fatal once clinical symptoms appear, and only a single case of survival of an individual without history of pre-or post-exposure vaccination has been recorded [2] . Rabies is globally endemic in domestic and/or wild animal populations, with the notable exception of a few regions where successful control and elimination strategies, of which oral vaccination had openUP (June 2007) been a key development, were employed [3] . In countries where rabies is still endemic in domestic dogs, human exposures are primarily linked to dog bites [3] and [4] . These regions also report the vast majority of human rabies cases, estimated in the range of 55,000 annually [3] and [4] . Although effective pre-and post-exposure prophylaxes for rabies in humans are available, multiple problems hamper the effective utilization thereof in many parts of the world [5] . These include the relative high costs of cell culture vaccines and anti-rabies virus immunoglobulins, and the logistics involved in acquiring the prophylaxis, especially in rural and remote communities with poor infrastructure. The only effective strategy for the control and prevention of rabies is the control of the disease in reservoir animals, i.e. domestic dogs or wildlife species [4] . Although parenteral vaccination campaigns for dogs can achieve much success, oral vaccination could improve the coverage of vaccination campaigns in those areas where many dogs (often community owned and free-roaming) are not easily accessible for parenteral vaccination. Oral vaccination also remains the only practical approach for the vaccination of wildlife reservoirs of the disease. The alternative, the indiscriminate killing of animals, is not only socially unacceptable, but has been shown to be relatively ineffective [6] .
A number of live attenuated vaccines have been evaluated as oral rabies vaccines for wildlife and for domestic dogs. These include SADBerne; SAD B19; SAD P5/88; ERA/BHK21; Vnukovo; SAG1 and SAG2, and more recently recombinant rabies virus vaccines generated by reverse genetics [7] and [8] . A recombinant vaccinia virus expressing the glycoprotein gene of the Evelyn-Rockitnicki-Abelseth strain (ERA) of rabies virus has been used as an oral vaccine for rabies in some European countries and also in the United States of America [9] , [10] and [11] . As many as 75 million doses of this vaccine have been distributed for the vaccination of wildlife-at present about 10 million doses are being distributed in the USA per year [4] . The strategic use of this vaccine aided in the establishment of an "immune" barrier for rabies in raccoons (Procyon lotor) and the elimination of the disease in coyotes (Canis latrans) in the USA [12] . Although these vaccines, especially SAG2 [13] and V-RG have been used extensively, these vaccines may be improved upon. The use of the vaccinia virus-based vaccines poses some safety issues. These include adverse effects associated with vaccinia vaccines, which could be lethal in immunocompromised individuals, and the potential openUP (June 2007) spread of the potent vaccine virus from the initial recipient to non-target recipients [4] , [14] and [15] . These fears were reiterated when a pregnant woman was infected with the vaccine virus through an encounter with vaccine-laden bait and subsequently developed virus-specific lesions and related symptoms [15] .
Clearly, a vaccine that could be used to immunize target animals orally but that would also be stable upon distribution and offer improved safety to target and non-target species alike would be ideal. Several factors contribute to the favorability of recombinant vaccines vectored by poxviruses: firstly, such vaccines are usually potent inducers of both arms of the immune response; secondly, the DNA genome of the virus is noninfectious and the virus relatively stable; thirdly, the poxvirus genome tolerates large insertions of foreign DNA (up to 30 kb), allowing for multivalent vaccine development; finally, these vaccines are relative easy to construct with modern genetic manipulation methodology [16] , [17] , [18] , [19] and [20] . For many years, attenuated forms or naturally host restricted members of the poxvirus group have been considered safer vectors for an effective rabies vaccine. These poxviruses in question are either naturally host restricted poxviruses, such as raccoon poxvirus; canary poxvirus and fowl poxvirus, or attenuated derivatives of vaccinia viruses such as NYVAC or modified vaccinia virus Ankara (MVA) [21] . Some of the above mentioned systems have been shown to be promising when evaluated as recombinant rabies vaccines [22] , [23] and [24] .
MVA has been identified as a vaccine vector of choice in many recent and ongoing vaccine development studies [25] and [26] . Additionally, MVA was used as a smallpox vaccine towards the end of the smallpox eradication effort and therefore has an established safety record for use in humans. Despite deliberate vaccination of high-risk vaccine recipients (i.e. eczematous, elderly or young), no untoward effects were reported and these reports have since been substantiated in clinical trials with MVA recombinants (e.g. [27] , [28] , [29] and [30] ). This highly attenuated strain of vaccinia virus was prepared from material isolated from an equine, pox-lesion in Ankara (Turkey), that was serially passaged in excess of 570 times on primary chick embryo fibroblast cultures [25] .
During passage on these cells, the virus adaptation resulted in six major genomic openUP (June 2007) deletions of about 31,000 base pairs (or 15% of the wild type Vaccinia virus Ankara genome) [31] and [32] . Most of the deleted and truncated genes have been shown to be immuno-regulators, or involved in the host range of the virus and multiple gene defects will have to be corrected for reversion to wild type [32] , [33] , [34] and [35] . MVA virus has been proven to be phenotypically and genotypically stable and although the virus fails to productively infect most mammalian cell lines tested (including cells of human origin), recombinant genes are still efficiently expressed in non-permissive cells [34] , [35] , [36] and [37] . MVA delivers antigens in a highly immunogenic way to stimulate both cellular and humoral responses [38] and its efficacy as a vaccine vector has been evaluated in a myriad of infectious disease and tumor models [26] , [39] , [40] and [41] .
Significantly, the use of MVA recombinants in the development of a prophylactic vaccine regimen for Human Immunodeficiency virus type 1, of which some recombinants are currently in clinical trails, have been described most recently [42] and [43] .
Recombinant MVA expressing pre-erythocytic Plasmodium berghei antigens is also envisioned as part of vaccination regime against malaria and is also currently being evaluated in clinical trials [44] , [45] and [46] . In addition, recombinant MVA viruses have been shown to be excellent boosters of vaccine induced immunity, particularly when DNA vaccine prime and recombinant MVA boost regimes are employed, but also when attenuated live vaccines are used as primary vaccine [46] , [47] and [48] .
In this study, the efficacy of a recombinant MVA expressing rabies virus glycoprotein as a candidate rabies vaccine was investigated. Using a murine model, the parenteral and 
Materials and methods

Viruses and cells
MVA (F6 isolate) was propagated in primary chicken embryo fibroblast culture (CEF) or BHK-21 (CCL-10). The primary CEF cultures were prepared from embryonated eggs as openUP (June 2007) described elsewhere [49] . Recombinant and parental vaccinia WR and Vacc Cop were passaged on Vero cell cultures (CCL-81). All cell cultures used in this study were grown in Minimal Essential Medium (MEM) supplemented with 4 mM glutamine and 2× MEM vitamin solution (all from Gibco, Invitrogen, USA). The medium was supplemented with 1× antibiotics (100 μg/ml penicillin, 100 μg/ml streptomycin and 250 μg/ml amphotericin) (Gibco, Invitrogen, USA) and 10% fetal bovine serum (FBS) (Hyclone, USA). Cultures were kept at 37 °C and at an atmosphere of 0.5% or 5% CO 2 .
Transfection studies were done on a primary chicken embryo cell line, CEC-32 [50] . 
Construction of a MVA transfer vector and cloning of a rabies virus glycoprotein gene in different vaccinia virus vectors
Protocols for molecular cloning of genes were followed as described elsewhere [51] . A MVA transfer vector that can be used to generate recombinant MVA with insertion in the site of deletion III, and can be used for transient selection for mycophenolic acid (MPA) resistance was generated. Relevant regions where obtained from another MVA transfer vector, pIIIdHRp7.5 [25] , [52] and [53] and a Lumpy Skin Disease virus transfer vector, pLSEG [54] . Shortly, sequences flanking the site of deletion III in the MVA genome, and the early-late poxvirus promoter, p7.5K were obtained from the MVA transfer vector, pIIIdHR-p7.5. The left flanking, flank 1, and the p7.5K promoter sequences were digested from pIIIdHR-p7.5 with BamH I (Promega, USA) and Spe I (Promega, USA) restriction endonucleases in a double digestion reaction setup. The fragment directionally inserted into the BamH I and Xba I sites of pUC18 (Roche, Germany) to generate pUCdelIIIflank1. The right flanking sequence, flank 2, was digested from pIIIdHR-p7. 
Preparation of recombinant vaccinia viruses expressing rabies virus glycoprotein
The methods for the generation and isolation of recombinant vaccinia viruses were adapted from previously described protocols [56] and [57] .
Transfection for the generation of recombinant viruses
Confluent monolayers of CEC-32 culture prepared in six well cluster cell culture plates (NUNC, Denmark) were infected with MVA or WR, respectively, at a MOI of 0.01.
Virus was absorbed for 90 min at 37 °C and an atmosphere of 5% CO 2 . Plasmid DNA was purified using spin columns (QIAquick ® Gel extraction Kit, QIAGEN, Germany) and spectrophotometrically analyzed for purity and concentration. 1 μg of DNA was used 
Immunization of dogs and raccoons
The ability of the MVA recombinant vaccine to induce an anamnestic response was 
Virus neutralization assay: rapid fluorescent focus inhibition test
The RFFIT protocol was adapted from Smith et al. [62] , but sera were set up with Challenge Virus Standard-11 as challenge in serum end-point dilutions of 8-serial, 10-fold dilutions. 
Results
Generation of recombinant vaccinia viruses
Humoral responses and survival in mice
In all experiments, the parental virus strains and MEM control groups failed to elicit virus-specific immune responses and all animals succumbed to rabies virus challenge.
When administered intramuscularly, the recombinant MVA elicited detectable humoral responses only at the highest experimental doses, viz 10 8 and 10 9 ffu (Table 1) .
Intramuscular doses of 10 9 ffu were however necessary to achieve 70-80% protection against lethal challenge (Table 1 ). In contrast, the experimental V-RG vaccine and the WR recombinant protected mice against lethal challenge at an intramuscular dosage of 10 7 pfu with the corresponding induction of measurable immune responses (Table 1) . Upon oral administration, the V-RG and WR vaccines offered 40-60% protection against severe, lethal challenge (Table 2 ) and the survival of these animals were reflected in serum neutralizing antibody responses (Table 1 and Table 2 ). The recombinant MVA, however, did not elicit any detectable humoral responses in mice that received the vaccine orally (Table 2 ) and no animals were protected against challenge. Table 2 .
openUP (June 2007)
Serological responses of mice after oral administration of vaccine and control viruses (Table 3 and Table 4 ). The geometric mean titers log base 10 (lowest value-highest value), as determined by RFFIT are provided.
Discussion
MVA has been identified as a safe and immunogenic carrier of foreign antigens and have in many applications become a vector of choice for recombinant vaccine development [25] and [26] . Ecogpt gene as a marker-as previously described for other vaccinia virus strains [63] .
The construction of marker-free recombinants is an important consideration if commercialization of such a recombinant as a vaccine is considered. An EGFP gene was also included in the construct. The use of EGFP for the screening of recombinants eliminates the need for colorimetric substrates and the application of other reagents to visualize the recombinant foci and only requires the use of a fluorescent microscope.
Expression of rabies glycoprotein from rMVA-RG, rWR-RG and the experimental V-RG was verified with an IFA employing monoclonals.
The recombinant MVA vaccine expressing a rabies virus glycoprotein gene, rMVA-RG, was initially tested in mice. It was found to be effective in mice when administered peripherally, but protection was only attained at doses of rMVA-RG virus as high as Critically, the recombinant MVA failed to elicit any detectable humoral responses upon oral administration of high doses and afforded no protection in our murine model.
Although more successful in this regard, the experimental V-RG and WR strain recombinants also did not provide full protection for all animals challenged with rabies virus. Since these vaccines have known efficacy in other models by the oral route, we concluded that our murine model was suboptimal for the testing of these oral vaccines against rabies and extended our investigation to include two species known to be susceptible to oral immunization with the vaccinia-based rabies vaccine, V-RG, viz. dogs and raccoons. However, when administrated orally, MVA recombinants also failed to elicit memory responses in previously vaccinated dogs and raccoons. In contrast, when openUP (June 2007) administered intramuscularly, the MVA recombinant enhanced immune responses in both species, boosting neutralizing antibody levels up to a 100-fold in pre-vaccinated and challenged raccoons and dogs. This finding appears to be in line with others, such as a study involving recombinant MVA expressing measles virus antigens, where MVA recombinants boosted low-levels of vaccine induced immunity much more efficiently than live attenuated measles virus vaccine [64] . Booster responses induced by MVA recombinants upon mucosal delivery, specifically after intranasal delivery, have also been indicated in macaques [65] and [66] . The most prominent value of recombinant MVA vaccines lie in this so-called "booster effect". As such, recombinant MVA have potential application in the field if used in conjunction with current live attenuated vaccines to attain long lasting protective responses. On the other hand, used as a primary vaccine, multiple doses may be required to attain efficacy upon peripheral administrations [67] .
Although successful vaccination through intragastric intubation with MVA recombinants and the efficacy of MVA recombinants via other mucosal routes have been shown in a number of studies [68] and [69] , successful vaccination directly via the oral route has not yet been investigated to our knowledge. An important part of the scope of this study was therefore to specifically determine the oral innocuity and immunogenicity of the rabies glycoprotein recombinant MVA.
The failure of oral immunization with MVA recombinants used in this study is most likely the result of the severe attenuation of the vaccine carrier leading to its lack of replication in the vaccine recipient. Considering the mechanics of mucosal administration of the vaccine virus, much virus is likely to be "lost" due to sloughing of cells in the mouth and throat. In the case of the V-RG and WR recombinant, the viruses are thought to be able to readily infect and replicate in these tissues, which may explain its potency via this route. A recombinant MVA vaccine may still be of use if included in immunization schemes in the presence of maternally derived antibodies (for example against rabies virus) or in the presence of pre-existing immunity to vaccinia virus. These constructs might therefore have a potential for the vaccination of younger animals with maternally derived immunity or previously vaccinated animals that require boosting [70] .
The specific use of such recombinants in immunocompromised individuals has also been openUP (June 2007) suggested and remains to be evaluated [71] . In conclusion, the immunogenicity and safety of recombinant MVA expressing rabies virus glycoprotein has been shown in this study. The recombinant vaccine proved immunogenic upon peripheral administration in mice, dogs and raccoons and the booster potential of MVA recombinants has also been confirmed in the application described here. However, increased safety came at the cost of efficacy and the lack of oral innocuity of the recombinant MVA rabies glycoprotein would rule this candidate unsuitable for replacement of V-RG or other effective oral rabies vaccines.
